HL Financial Services LLC increased its position in shares of Bristol-Myers Squibb Co. (NYSE:BMY) by 0.8% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 360,221 shares of the biopharmaceutical company’s stock after buying an additional 2,901 shares during the period. HL Financial Services LLC’s holdings in Bristol-Myers Squibb were worth $26,494,000 as of its most recent filing with the SEC.

A number of other large investors also recently made changes to their positions in BMY. Bank of Montreal Can acquired a new position in Bristol-Myers Squibb during the second quarter worth approximately $154,732,000. IBM Retirement Fund increased its position in Bristol-Myers Squibb by 1.1% in the second quarter. IBM Retirement Fund now owns 219,448 shares of the biopharmaceutical company’s stock worth $16,627,000 after buying an additional 2,421 shares during the period. Howard Capital Management increased its position in Bristol-Myers Squibb by 0.7% in the second quarter. Howard Capital Management now owns 153,499 shares of the biopharmaceutical company’s stock worth $11,290,000 after buying an additional 1,068 shares during the period. Handelsbanken Fonder AB increased its position in Bristol-Myers Squibb by 19.4% in the second quarter. Handelsbanken Fonder AB now owns 141,365 shares of the biopharmaceutical company’s stock worth $10,397,000 after buying an additional 23,000 shares during the period. Finally, Chevy Chase Trust Holdings Inc. increased its position in Bristol-Myers Squibb by 1.1% in the second quarter. Chevy Chase Trust Holdings Inc. now owns 1,460,780 shares of the biopharmaceutical company’s stock worth $107,440,000 after buying an additional 15,313 shares during the period. Institutional investors own 72.88% of the company’s stock.

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Bristol-Myers Squibb Co. (NYSE:BMY) traded down 0.52% during trading on Tuesday, reaching $49.55. 24,530,192 shares of the company’s stock were exchanged. The firm has a market capitalization of $82.79 billion, a price-to-earnings ratio of 28.98 and a beta of 0.75. The stock has a 50-day moving average price of $56.14 and a 200 day moving average price of $66.76. Bristol-Myers Squibb Co. has a 52 week low of $49.50 and a 52 week high of $77.12.

Bristol-Myers Squibb (NYSE:BMY) last announced its earnings results on Thursday, July 28th. The biopharmaceutical company reported $0.69 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.66 by $0.03. The business had revenue of $4.90 billion for the quarter, compared to analyst estimates of $4.60 billion. Bristol-Myers Squibb had a net margin of 16.63% and a return on equity of 24.92%. The company’s revenue for the quarter was up 17.2% compared to the same quarter last year. During the same period last year, the firm posted $0.53 earnings per share. Equities research analysts forecast that Bristol-Myers Squibb Co. will post $2.63 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, November 1st. Stockholders of record on Friday, October 7th will be given a dividend of $0.38 per share. The ex-dividend date of this dividend is Wednesday, October 5th. This represents a $1.52 dividend on an annualized basis and a dividend yield of 3.07%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is presently 87.36%.

BMY has been the topic of a number of research reports. Deutsche Bank AG reissued a “hold” rating on shares of Bristol-Myers Squibb in a research report on Wednesday, June 15th. BMO Capital Markets reissued a “market perform” rating and set a $60.00 target price on shares of Bristol-Myers Squibb in a research report on Saturday, September 3rd. Credit Suisse Group AG reaffirmed a “hold” rating and issued a $63.00 price objective on shares of Bristol-Myers Squibb in a research report on Monday, August 15th. Zacks Investment Research downgraded shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research report on Monday, July 11th. Finally, Morgan Stanley reaffirmed a “hold” rating on shares of Bristol-Myers Squibb in a research report on Thursday, August 25th. Two research analysts have rated the stock with a sell rating, twelve have assigned a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the company. Bristol-Myers Squibb currently has a consensus rating of “Hold” and a consensus price target of $69.31.

In other news, Director Lamberto Andreotti sold 21,600 shares of the firm’s stock in a transaction that occurred on Thursday, September 8th. The shares were sold at an average price of $56.87, for a total transaction of $1,228,392.00. Following the transaction, the director now directly owns 334,499 shares in the company, valued at $19,022,958.13. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 0.24% of the company’s stock.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

5 Day Chart for NYSE:BMY

Receive News & Stock Ratings for Bristol-Myers Squibb Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Co. and related stocks with our FREE daily email newsletter.